by jmanor | Aug 25, 2023 | White Papers
This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient health with respect to small molecule drugs. Initial evidence potentially suggests that the cutbacks in R&D have...
by sfrazee | Jun 10, 2023 | White Papers
This policy brief reviews the evidence on the health and cost impacts of multi-cancer early detection (MCED) tests, and the implications for proposed legislation to enhance their utilization in Medicare. We find that the evidence base suggests that MCED screening...
by jmanor | Jun 7, 2023 | White Papers
Historically, Medicare has reimbursed drugs approved by the Food and Drug Administration (FDA) including drugs granted accelerated approval. In 2021, FDA granted accelerated approval to plaque-targeting treatments for Alzheimer’s disease (AD), but the Centers for...
by susuguo | May 2, 2023 | Journal, White Papers
The extent of voluntary cooperation in the presence of externalities is shown as an equilib- rium outcome in the supply and demand framework. The analysis uses familiar ingredients to provide a new way of understanding the results of the extensive literature beginning...
by jmanor | Apr 3, 2023 | White Papers
The Biden administration has made reducing health disparities a major goal of its health care agenda. This paper provides analysis of whether and how biopharmaceutical innovation has historically reduced disparities in health outcomes and how reducing such innovation...
by jmanor | Feb 15, 2023 | White Papers
This paper provides the first quantitative economic models of pharmacy benefit management (PBM) regulation. Indeed, few economic models of the pharmaceutical industry even acknowledge that drug benefits are managed and that companies specialize in benefit management....
